California State Teachers Retirement System Sells 5,406 Shares of Gilead Sciences, Inc. $GILD

California State Teachers Retirement System trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,908,886 shares of the biopharmaceutical company's stock after selling 5,406 shares during the period. California State Teachers Retirement System owned approximately 0.15% of Gilead Sciences worth $241,168,657 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $25,000. Persistent Asset Partners Ltd acquired a new position in Gilead Sciences in the 2nd quarter valued at approximately $25,000. Kimelman & Baird LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at approximately $25,000. Wealth Preservation Advisors LLC raised its stake in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Wiser Advisor Group LLC bought a new position in Gilead Sciences during the second quarter worth about $30,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, Director Anthony Welters sold 18,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares of the company's stock, valued at $1,916,306.28. This represents a 58.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares of the company's stock, valued at $22,918,780.56. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 99,000 shares of company stock worth $13,747,860 in the last quarter. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. Maxim Group upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. Barclays cut their price target on Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 29th. Morgan Stanley dropped their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a research report on Monday, July 27th. Wall Street Zen cut Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, September 5th. Finally, Zacks Research upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $158.78.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and the Pan American Health Organization agreed to expand access to lenacapavir, Gilead’s long-acting HIV-prevention medicine, across Latin America and the Caribbean. The agreement strengthens the drug’s public-health reach and could support long-term adoption, although commercial revenue terms were not specified. Reuters article
• Positive Sentiment: Gilead is distributing an $0.82-per-share cash dividend, payable September 29. The payout supports the stock’s income appeal and reflects continued shareholder returns. Gilead dividend analysis
• Positive Sentiment: Unusually heavy options activity included 12,503 purchased call contracts, 54% above the average volume. This indicates increased speculative interest in further upside, though options activity is not a guarantee of future performance.
• Neutral Sentiment: Gilead presented at Morgan Stanley’s 24th Annual Global Healthcare Conference, keeping management and the company’s HIV pipeline in focus. The available report is a transcript and does not identify a major new financial outlook change. Morgan Stanley conference transcript
• Neutral Sentiment: Gilead recently gained 1.88% while the broader market weakened, suggesting relative strength and continued investor interest in its growth and HIV-treatment prospects. However, the company’s five-year share-price gain of roughly 146.6% has raised questions about whether sales growth fully supports the current valuation.
• Negative Sentiment: The stock entered its ex-dividend date, meaning new buyers will not receive the $0.82 distribution. The resulting mechanical adjustment can create short-term downward pressure even though it does not change Gilead’s underlying business value. Gilead dividend ex-date article

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.46 on Tuesday, reaching $145.96. The company's stock had a trading volume of 1,809,641 shares, compared to its average volume of 6,901,857. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a 50-day simple moving average of $138.82 and a 200 day simple moving average of $136.18. The company has a market cap of $180.98 billion, a P/E ratio of -54.68 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business's revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences's payout ratio is currently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.